|Bid||285.00 x 1200|
|Ask||292.40 x 1000|
|Day's Range||282.63 - 292.41|
|52 Week Range||57.15 - 315.45|
|Beta (5Y Monthly)||-0.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||303.00|
Subscribe to Yahoo Finance Plus to view Fair Value for MDGL
With the business potentially at an important milestone, we thought we'd take a closer look at Madrigal...
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.
Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.